The RNA advantage: A multimodal approach to accelerating oncology R&D

Rafael Rosengarten is CEO and co-founder of Genialis, the company revolutionizing precision oncology with RNA and AI. Before leading Genialis’ effort to realize the promise of precision medicine, he spent nearly 20 years in biomedical research, publishing in the fields of evolution, immunology, bioengineering and genetics. Dr. Rosengarten is also a board member and co-founder of the Alliance for AI in Healthcare (AAIH), a non-profit global advocacy organization. Rafael attended Dartmouth College before earning his doctorate from Yale University, where he was an NSF Graduate Research Fellow, and received postdoctoral training in Jay Keasling’s synthetic biology group at Lawrence Berkeley National Laboratory, Joint BioEnergy Institute (JBEI).

Dr. Sandip Patel, MD is a Professor at UCSD and a medical oncologist focused on the early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials. His lab focuses on computational immunopathology to derive spatial immune signatures that can inform novel immune target discovery. Dr. Patel earned his medical degree at Baylor College of Medicine while performing research at MD Anderson Cancer Center. He completed a residency in Internal Medicine at UCLA Medical Center. He completed a fellowship in Medical Oncology and Hematology at Duke University Medical Center.

Justin Guinney is the Senior Vice President of Cancer Genomics at Tempus AI where he leads research and development of precision oncology models using Tempus’s large multimodal database. Dr. Guinney retains positions as an Affiliate Associate Professor at the University of Washington, and Director of the DREAM Challenges. He received a BA in history & pre-medicine from the University of Pennsylvania, a BS in electrical engineering from the University of Illinois Urbana-Champaign, and a PhD in computational biology and bioinformatics from Duke University.

Dr. Maria Berezina is the VP of Real World Data at Tempus, where she oversees clinical data structuring, data model development, and the RWD/RWE analytics. With a decade of experience in oncology analytics, she provides business and research insights to large pharmaceutical companies, biotechs, start-ups, investment funds, and insurance providers. Over the past five years, she has built and led RWD analytics and data science teams, overseeing numerous retrospective studies for life science partners. Her blend of technical expertise, deep knowledge of clinical care in oncology, and experience in RWE generation ensures that Tempus' multi-modal RWD product aligns with life science research goals. She holds a bachelor's degree in Electrical Engineering from the University of Massachusetts Lowell and a doctoral degree in Biomedical Engineering from the Harvard-MIT Division of Health Science and Technology.

Dr. Kathleen Burke is a Senior Director of Computational Biology supporting the Tempus strategic alliances. This team collaborates across companies to drive multimodal analysis that accelerates projects throughout the discovery pipeline by enhancing trial design, broadening biomarker testing, investigating combination opportunities, identifying novel targets, and more. Before coming to Tempus, Kathleen worked at AstraZeneca in the bioinformatics group supporting the Early Oncology Translational Medicine, analyzing molecular data for Hematology drug teams with a focus on determining mechanisms of resistance to Acalabrutinib. She received her PhD in Biomedical Engineering from the University of Rochester and performed post-doctoral research at Memorial Sloan Kettering Cancer Center, understanding the genetic landscape of rare breast/uterine carcinomas.